XML 30 R21.htm IDEA: XBRL DOCUMENT
v3.22.2.2

SEGMENT INFORMATION | 9 Months Ended
--- | ---
Sep. 30, 2022
Segment Reporting [Abstract] |
SEGMENT INFORMATION | SEGMENT INFORMATION We manage our business with three reportable segments: Retail, Group and Specialty, and Healthcare Services. The reportable segments are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts. In addition, the Retail segment also includes our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, including Temporary Assistance for Needy Families, or TANF, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. The Group and Specialty segment consists of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO products. In addition, our Group and Specialty segment includes our military services business, primarily our TRICARE T2017 East Region contract. The Healthcare Services segment includes pharmacy, provider, and home services, along with other services and capabilities to promote wellness and advance population health. The segment also includes the company's strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs. Our Healthcare Services intersegment revenues primarily relate to managing prescription drug coverage for members of our other segments through Humana Pharmacy Solutions®, or HPS, and includes the operations of Humana Pharmacy, Inc., our mail order pharmacy business. These revenues consist of the prescription price (ingredient cost plus dispensing fee), including the portion to be settled with the member (co-share) or with the government (subsidies), plus any associated administrative fees. Services revenue related to the distribution of prescriptions by third party retail pharmacies in our networks are recognized when the claim is processed and product revenues from dispensing prescriptions from our mail order pharmacies are recorded when the prescription or product is shipped. Our pharmacy operations, which are responsible for designing pharmacy benefits, including defining member co-share responsibilities, determining formulary listings, contracting with retail pharmacies, confirming member eligibility, reviewing drug utilization, and processing claims, act as a principal in the arrangement on behalf of members in our other segments. As principal, our Healthcare Services segment reports revenues on a gross basis, including co-share amounts from members collected by third party retail pharmacies at the point of service. In addition, our Healthcare Services intersegment revenues include revenues earned by certain owned providers derived from risk-based and non-risk-based managed care agreements with our health plans. Under risk based agreements, the provider receives a monthly capitated fee that varies depending on the demographics and health status of the member, for each member assigned to these owned providers by our health plans. The owned provider assumes the economic risk of funding the assigned members’ healthcare services. Under non risk-based agreements, our health plans retain the economic risk of funding the assigned members' healthcare services. Our Healthcare Services segment reports provider services revenue associated with risk-based agreements on a gross basis, whereby capitation fee revenue is recognized in the period in which the assigned members are entitled to receive healthcare services. Provider services revenue associated with non-risk-based agreements are presented net of associated healthcare costs. We present our condensed consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $5.4 billion and $5.0 billion for the three months ended September 30, 2022 and 2021, respectively. For the nine months ended September 30, 2022 and 2021 these amounts were $14.2 billion and $12.9 billion, respectively. In addition, depreciation and amortization expense associated with certain businesses in our Healthcare Services segment delivering benefits to our members, primarily associated with our provider services and pharmacy operations, are included with benefits expense. The amount of this expense was $30 million and $28 million for the three months ended September 30, 2022 and 2021, respectively. For the nine months ended September 30, 2022 and 2021, the amount of this expense was $89 million and $80 million, respectively. Other than those described previously, the accounting policies of each segment are the same. For additional information regarding our accounting policies refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2021 Form 10-K. Transactions between reportable segments primarily consist of sales of services rendered by our Healthcare Services segment, primarily pharmacy, provider, and home solutions services, to our Retail and Group and Specialty segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below. Our segment results were as follows for the three and nine months ended September 30, 2022 and 2021:
| Retail |  | Group and Specialty |  | Healthcare Services |  | Eliminations/ Corporate |  | Consolidated
Three months ended September 30, 2022 | (in millions)
External revenues |  |  |  |  |  |  |  |
Premiums: |  |  |  |  |  |  |  |  |
Individual Medicare Advantage | $ | 16,007 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 16,007 |
Group Medicare Advantage | 1,792 |  |  | — |  |  | — |  |  | — |  |  | 1,792 |
Medicare stand-alone PDP | 534 |  |  | — |  |  | — |  |  | — |  |  | 534 |
Total Medicare | 18,333 |  |  | — |  |  | — |  |  | — |  |  | 18,333 |
Fully-insured | 188 |  |  | 912 |  |  | — |  |  | — |  |  | 1,100 |
Specialty | — |  |  | 425 |  |  | — |  |  | — |  |  | 425 |
Medicaid and other | 1,610 |  |  | — |  |  | — |  |  | — |  |  | 1,610 |
Total premiums | 20,131 |  |  | 1,337 |  |  | — |  |  | — |  |  | 21,468 |
Services revenue: |  |  |  |  |  |  |  |  |
Home solutions | — |  |  | — |  |  | 519 |  |  | — |  |  | 519 |
Provider | — |  |  | — |  |  | 159 |  |  | — |  |  | 159 |
ASO and other | 10 |  |  | 197 |  |  | — |  |  | — |  |  | 207 |
Pharmacy | — |  |  | — |  |  | 274 |  |  | — |  |  | 274 |
Total services revenue | 10 |  |  | 197 |  |  | 952 |  |  | — |  |  | 1,159 |
Total external revenues | 20,141 |  |  | 1,534 |  |  | 952 |  |  | — |  |  | 22,627 |
Intersegment revenues |  |  |  |  |  |  |  |  |
Services | — |  |  | 14 |  |  | 5,466 |  |  | (5,480) |  |  | — |
Products | — |  |  | — |  |  | 2,459 |  |  | (2,459) |  |  | — |
Total intersegment revenues | — |  |  | 14 |  |  | 7,925 |  |  | (7,939) |  |  | — |
Investment income | 48 |  |  | 3 |  |  | 3 |  |  | 118 |  |  | 172 |
Total revenues | 20,189 |  |  | 1,551 |  |  | 8,880 |  |  | (7,821) |  |  | 22,799 |
Operating expenses: |  |  |  |  |  |  |  |  |
Benefits | 17,420 |  |  | 1,052 |  |  | — |  |  | (88) |  |  | 18,384 |
Operating costs | 1,903 |  |  | 427 |  |  | 8,435 |  |  | (7,704) |  |  | 3,061 |
Depreciation and amortization | 137 |  |  | 23 |  |  | 50 |  |  | (28) |  |  | 182 |
Total operating expenses | 19,460 |  |  | 1,502 |  |  | 8,485 |  |  | (7,820) |  |  | 21,627 |
Income (loss) from operations | 729 |  |  | 49 |  |  | 395 |  |  | (1) |  |  | 1,172 |
Gain on sale of KAH Hospice | — |  |  | — |  |  | (240) |  |  | — |  |  | (240) |
Interest expense | — |  |  | — |  |  | — |  |  | 102 |  |  | 102 |
Other expense, net | — |  |  | — |  |  | — |  |  | 13 |  |  | 13 |
Income (loss) before income taxes and equity in net earnings | 729 |  |  | 49 |  |  | 635 |  |  | (116) |  |  | 1,297 |
Equity in net earnings (losses) | 8 |  |  | — |  |  | (5) |  |  | — |  |  | 3 |
Segment earnings (loss) | $ | 737 |  |  | $ | 49 |  |  | $ | 630 |  |  | $ | (116) |  |  | $ | 1,300 |
Net loss attributable to noncontrolling interests | 2 |  |  | — |  |  | — |  |  | — |  |  | 2 |
Segment earnings (loss) attributable to Humana | $ | 739 |  |  | $ | 49 |  |  | $ | 630 |  |  | $ | (116) |  |  | $ | 1,302 |
| Retail |  | Group and Specialty |  | Healthcare Services |  | Eliminations/ Corporate |  | Consolidated
Three months ended September 30, 2021 | (in millions)
External revenues |  |  |  |  |  |  |  |
Premiums: |  |  |  |  |  |  |  |  |
Individual Medicare Advantage | $ | 14,642 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 14,642 |
Group Medicare Advantage | 1,737 |  |  | — |  |  | — |  |  | — |  |  | 1,737 |
Medicare stand-alone PDP | 541 |  |  | — |  |  | — |  |  | — |  |  | 541 |
Total Medicare | 16,920 |  |  | — |  |  | — |  |  | — |  |  | 16,920 |
Fully-insured | 185 |  |  | 1,052 |  |  | — |  |  | — |  |  | 1,237 |
Specialty | — |  |  | 432 |  |  | — |  |  | — |  |  | 432 |
Medicaid and other | 1,296 |  |  | — |  |  | — |  |  | — |  |  | 1,296 |
Total premiums | 18,401 |  |  | 1,484 |  |  | — |  |  | — |  |  | 19,885 |
Services revenue: |  |  |  |  |  |  |  |  |
Home solutions | — |  |  | — |  |  | 374 |  |  | — |  |  | 374 |
Provider | — |  |  | — |  |  | 110 |  |  | — |  |  | 110 |
ASO and other | — |  |  | 198 |  |  | — |  |  | — |  |  | 198 |
Pharmacy | — |  |  | — |  |  | 163 |  |  | — |  |  | 163 |
Total services revenue | — |  |  | 198 |  |  | 647 |  |  | — |  |  | 845 |
Total external revenues | 18,401 |  |  | 1,682 |  |  | 647 |  |  | — |  |  | 20,730 |
Intersegment revenues |  |  |  |  |  |  |  |  |
Services | 1 |  |  | 10 |  |  | 5,087 |  |  | (5,098) |  |  | — |
Products | — |  |  | — |  |  | 2,303 |  |  | (2,303) |  |  | — |
Total intersegment revenues | 1 |  |  | 10 |  |  | 7,390 |  |  | (7,401) |  |  | — |
Investment income (loss) | 38 |  |  | 3 |  |  | 1 |  |  | (75) |  |  | (33) |
Total revenues | 18,440 |  |  | 1,695 |  |  | 8,038 |  |  | (7,476) |  |  | 20,697 |
Operating expenses: |  |  |  |  |  |  |  |  |
Benefits | 16,207 |  |  | 1,282 |  |  | — |  |  | (173) |  |  | 17,316 |
Operating costs | 1,669 |  |  | 421 |  |  | 7,634 |  |  | (7,121) |  |  | 2,603 |
Depreciation and amortization | 108 |  |  | 20 |  |  | 46 |  |  | (24) |  |  | 150 |
Total operating expenses | 17,984 |  |  | 1,723 |  |  | 7,680 |  |  | (7,318) |  |  | 20,069 |
Income (loss) from operations | 456 |  |  | (28) |  |  | 358 |  |  | (158) |  |  | 628 |
Interest expense | — |  |  | — |  |  | — |  |  | 88 |  |  | 88 |
Other income, net | — |  |  | — |  |  | — |  |  | (1,096) |  |  | (1,096) |
Income (loss) before income taxes and equity in net earnings | 456 |  |  | (28) |  |  | 358 |  |  | 850 |  |  | 1,636 |
Equity in net earnings | — |  |  | — |  |  | 15 |  |  | — |  |  | 15 |
Segment earnings (loss) | $ | 456 |  |  | $ | (28) |  |  | $ | 373 |  |  | $ | 850 |  |  | $ | 1,651 |
| Retail |  | Group and Specialty |  | Healthcare Services |  |  |  |  |  | Eliminations/ Corporate |  | Consolidated
Nine months ended September 30, 2022 | (in millions)
External revenues |  |  |  |  |  |  |  |  |  |  |  |
Premiums: |  |  |  |  |  |  |  |  |  |  |  |  |
Individual Medicare Advantage | $ | 49,751 |  |  | $ | — |  |  | $ | — |  |  |  |  |  |  | $ | — |  |  | $ | 49,751 |
Group Medicare Advantage | 5,524 |  |  | — |  |  | — |  |  |  |  |  |  | — |  |  | 5,524 |
Medicare stand-alone PDP | 1,779 |  |  | — |  |  | — |  |  |  |  |  |  | — |  |  | 1,779 |
Total Medicare | 57,054 |  |  | — |  |  | — |  |  |  |  |  |  | — |  |  | 57,054 |
Fully-insured | 555 |  |  | 2,827 |  |  | — |  |  |  |  |  |  | — |  |  | 3,382 |
Specialty | — |  |  | 1,281 |  |  | — |  |  |  |  |  |  | — |  |  | 1,281 |
Medicaid and other | 4,720 |  |  | — |  |  | — |  |  |  |  |  |  | — |  |  | 4,720 |
Total premiums | 62,329 |  |  | 4,108 |  |  | — |  |  |  |  |  |  | — |  |  | 66,437 |
Services revenue: |  |  |  |  |  |  |  |  |  |  |  |  |
Home solutions | — |  |  | — |  |  | 1,997 |  |  |  |  |  |  | — |  |  | 1,997 |
Provider services | — |  |  | — |  |  | 409 |  |  |  |  |  |  | — |  |  | 409 |
ASO and other | 24 |  |  | 588 |  |  | — |  |  |  |  |  |  | — |  |  | 612 |
Pharmacy solutions | — |  |  | — |  |  | 754 |  |  |  |  |  |  | — |  |  | 754 |
Total services revenue | 24 |  |  | 588 |  |  | 3,160 |  |  |  |  |  |  | — |  |  | 3,772 |
Total external revenues | 62,353 |  |  | 4,696 |  |  | 3,160 |  |  |  |  |  |  | — |  |  | 70,209 |
Intersegment revenues |  |  |  |  |  |  |  |  |  |  |  |  |
Services | — |  |  | 42 |  |  | 15,970 |  |  |  |  |  |  | (16,012) |  |  | — |
Products | — |  |  | — |  |  | 7,394 |  |  |  |  |  |  | (7,394) |  |  | — |
Total intersegment revenues | — |  |  | 42 |  |  | 23,364 |  |  |  |  |  |  | (23,406) |  |  | — |
Investment income | 133 |  |  | 10 |  |  | 6 |  |  |  |  |  |  | 73 |  |  | 222 |
Total revenues | 62,486 |  |  | 4,748 |  |  | 26,530 |  |  |  |  |  |  | (23,333) |  |  | 70,431 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |
Benefits | 54,352 |  |  | 3,143 |  |  | — |  |  |  |  |  |  | (387) |  |  | 57,108 |
Operating costs | 5,309 |  |  | 1,255 |  |  | 25,089 |  |  |  |  |  |  | (22,533) |  |  | 9,120 |
Depreciation and amortization | 391 |  |  | 68 |  |  | 153 |  |  |  |  |  |  | (85) |  |  | 527 |
Total operating expenses | 60,052 |  |  | 4,466 |  |  | 25,242 |  |  |  |  |  |  | (23,005) |  |  | 66,755 |
Income (loss) from operations | 2,434 |  |  | 282 |  |  | 1,288 |  |  |  |  |  |  | (328) |  |  | 3,676 |
Gain on sale of KAH Hospice | — |  |  | — |  |  | (240) |  |  |  |  |  |  | — |  |  | (240) |
Interest expense | — |  |  | — |  |  | — |  |  |  |  |  |  | 293 |  |  | 293 |
Other income, net | — |  |  | — |  |  | — |  |  |  |  |  |  | (16) |  |  | (16) |
Income (loss) before income taxes and equity in net earnings | 2,434 |  |  | 282 |  |  | 1,528 |  |  |  |  |  |  | (605) |  |  | 3,639 |
Equity in net earnings (losses) | 16 |  |  | — |  |  | (15) |  |  |  |  |  |  | — |  |  | 1 |
Segment earnings (loss) | $ | 2,450 |  |  | $ | 282 |  |  | $ | 1,513 |  |  |  |  |  |  | $ | (605) |  |  | $ | 3,640 |
Net loss (income) attributable to noncontrolling interests | 2 |  |  | — |  |  | (1) |  |  |  |  |  |  | — |  |  | 1 |
Segment earnings (loss) attributable to Humana | $ | 2,452 |  |  | $ | 282 |  |  | $ | 1,512 |  |  |  |  |  |  | $ | (605) |  |  | $ | 3,641 |
| Retail |  | Group and Specialty |  | Healthcare Services |  | Eliminations/ Corporate |  | Consolidated
Nine months ended September 30, 2021 | (in millions)
External Revenues |  |  |  |  |  |  |  |
Premiums: |  |  |  |  |  |  |  |  |
Individual Medicare Advantage | $ | 44,042 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 44,042 |
Group Medicare Advantage | 5,267 |  |  | — |  |  | — |  |  | — |  |  | 5,267 |
Medicare stand-alone PDP | 1,867 |  |  | — |  |  | — |  |  | — |  |  | 1,867 |
Total Medicare | 51,176 |  |  | — |  |  | — |  |  | — |  |  | 51,176 |
Fully-insured | 545 |  |  | 3,229 |  |  | — |  |  | — |  |  | 3,774 |
Specialty | — |  |  | 1,298 |  |  | — |  |  | — |  |  | 1,298 |
Medicaid and other | 3,739 |  |  | — |  |  | — |  |  | — |  |  | 3,739 |
Total premiums | 55,460 |  |  | 4,527 |  |  | — |  |  | — |  |  | 59,987 |
Services revenue: |  |  |  |  |  |  |  |  |
Home solutions | — |  |  | — |  |  | 423 |  |  | — |  |  | 423 |
Provider services | — |  |  | — |  |  | 298 |  |  | — |  |  | 298 |
ASO and other | 17 |  |  | 582 |  |  | — |  |  | — |  |  | 599 |
Pharmacy solutions | — |  |  | — |  |  | 482 |  |  | — |  |  | 482 |
Total services revenue | 17 |  |  | 582 |  |  | 1,203 |  |  | — |  |  | 1,802 |
Total external revenues | 55,477 |  |  | 5,109 |  |  | 1,203 |  |  | — |  |  | 61,789 |
Intersegment revenues |  |  |  |  |  |  |  |  |
Services | 1 |  |  | 30 |  |  | 14,838 |  |  | (14,869) |  |  | — |
Products | — |  |  | — |  |  | 6,716 |  |  | (6,716) |  |  | — |
Total intersegment revenues | 1 |  |  | 30 |  |  | 21,554 |  |  | (21,585) |  |  | — |
Investment income | 155 |  |  | 11 |  |  | 3 |  |  | 52 |  |  | 221 |
Total revenues | 55,633 |  |  | 5,150 |  |  | 22,760 |  |  | (21,533) |  |  | 62,010 |
Operating expenses: |  |  |  |  |  |  |  |  |
Benefits | 48,574 |  |  | 3,674 |  |  | — |  |  | (487) |  |  | 51,761 |
Operating costs | 4,653 |  |  | 1,227 |  |  | 21,749 |  |  | (20,903) |  |  | 6,726 |
Depreciation and amortization | 320 |  |  | 63 |  |  | 127 |  |  | (74) |  |  | 436 |
Total operating expenses | 53,547 |  |  | 4,964 |  |  | 21,876 |  |  | (21,464) |  |  | 58,923 |
Income (loss) from operations | 2,086 |  |  | 186 |  |  | 884 |  |  | (69) |  |  | 3,087 |
Interest expense | — |  |  | — |  |  | — |  |  | 235 |  |  | 235 |
Other income, net | — |  |  | — |  |  | — |  |  | (562) |  |  | (562) |
Income before income taxes and equity in net earnings | 2,086 |  |  | 186 |  |  | 884 |  |  | 258 |  |  | 3,414 |
Equity in net earnings | — |  |  | — |  |  | 69 |  |  | — |  |  | 69 |
Segment earnings | $ | 2,086 |  |  | $ | 186 |  |  | $ | 953 |  |  | $ | 258 |  |  | $ | 3,483 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration